Dementia and Alzheimer Disease

In an extensive analysis, investigators link antipsychotic initiators with more days in the hospital for Alzheimer disease patients.

Higmark Interactive will now be able to market their full suite of EQ software modules.

There are many factors that make living at home with Alzheimer disease difficult.

A panel discussion on a growing public concern over our ability to treat and prevent dementia.

The aim of the “Alzheimer’s Disease Exposome” will be to identify new interactions of risk genes for future studies.

Acadia Pharmaceuticals has announced positive findings for time to psychosis relapse in dementia patients, which resulted in the trial's early end.

Benzodiazepines are a common yet not very well understood drug class for elderly patients with insomnia.

Using a variety of tests to measure cognitive changes, investigators find that gender and education level does not impact cognitive decline as much as health and lifestyle factors.

Findings from the Insight 46 study reveal blood pressure changes during midlife can lead to poorer brain health as a patient gets older.

The association of depression symptoms with cognition and cortical amyloid measurements could lead to better therapies to prevent Alzheimer disease.

Considerations for improving upon the diagnosis and management of Alzheimer disease.

Alkahest announces positive top-line data for phase 2 study to treat mild-to-moderate Alzheimer disease.

Socially active people in the their 50s and 60s have a lower risk of developing dementia, according to a new study.

New model predicts patients at risk of developing Alzheimer disease up to 2 years in the future.

An overview of exciting, upcoming therapies that may be of interest for the treatment of Alzheimer disease.

Experts discuss the status of clinical trials that explore various monoclonal antibody therapies and BACE inhibitors for the treatment of Alzheimer disease.

New study links serum-based liver function markers with known Alzheimer disease biomarkers.

The rationale for investigating monoclonal antibodies and BACE inhibitors for the treatment of patients with Alzheimer disease.